4-(4-chloro-2-(1-(1-ethylazetidin-3-yl)-1H-pyrazol-5-yl)phenoxy)-3-cyano-N-(thiazol-4-yl)benzenesulfonamide

ID: ALA2324748

Chembl Id: CHEMBL2324748

PubChem CID: 46841648

Max Phase: Preclinical

Molecular Formula: C24H21ClN6O3S2

Molecular Weight: 541.06

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CCN1CC(n2nccc2-c2cc(Cl)ccc2Oc2ccc(S(=O)(=O)Nc3cscn3)cc2C#N)C1

Standard InChI:  InChI=1S/C24H21ClN6O3S2/c1-2-30-12-18(13-30)31-21(7-8-28-31)20-10-17(25)3-5-23(20)34-22-6-4-19(9-16(22)11-26)36(32,33)29-24-14-35-15-27-24/h3-10,14-15,18,29H,2,12-13H2,1H3

Standard InChI Key:  OGBDDOBYHJYBFF-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA2324748

   4-{4-Chloro-2-[1-(1-ethylazetidin-3-yl)-1H-pyrazol-5-yl]phenoxy}-3-cyano-N-1,3-thiazol-4-ylbenzenesulfonamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 541.06

Molecular Weight (Monoisotopic): 540.0805

AlogP: 5.00

#Rotatable Bonds: 8

Polar Surface Area: 113.14

Molecular Species: ACID

HBA: 9

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 9

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 6.26

CX Basic pKa: 7.29

CX LogP: 3.01

CX LogD: 3.02

Aromatic Rings: 4

Heavy Atoms: 36

QED Weighted: 0.33

Np Likeness Score: -1.89

References

1. Norinder U, Ek ME..  (2013)  QSAR investigation of NaV1.7 active compounds using the SVM/Signature approach and the Bioclipse Modeling platform.,  23  (1): [PMID:23177785] [10.1016/j.bmcl.2012.10.102]

2. Swain NA, Batchelor D, Beaudoin S, Bechle BM, Bradley PA, Brown AD, Brown B, Butcher KJ, Butt RP, Chapman ML, Denton S, Ellis D, Galan SRG, Gaulier SM, Greener BS, de Groot MJ, Glossop MS, Gurrell IK, Hannam J, Johnson MS, Lin Z, Markworth CJ, Marron BE, Millan DS, Nakagawa S, Pike A, Printzenhoff D, Rawson DJ, Ransley SJ, Reister SM, Sasaki K, Storer RI, Stupple PA, West CW..  (2017)  Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.,  60  (16): [PMID:28682065] [10.1021/acs.jmedchem.7b00598]

3. Tess DA,Eng H,Kalgutkar AS,Litchfield J,Edmonds DJ,Griffith DA,Varma MVS.  (2020)  Predicting the Human Hepatic Clearance of Acidic and Zwitterionic Drugs.,  63  (20): [PMID:32985885] [10.1021/acs.jmedchem.0c01033]

Source

Source(1):

• Scientific Literature